Short-Term Changes in Skeletal Muscle Mass After Anthracycline Administration in Adolescent and Young Adult Sarcoma Patients.

Autor: Wooten SV; Department of Pediatrics Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Roth M; Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Livingston JA; Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.; Department of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Hildebrandt MAT; Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Chandra J; Department of Pediatrics Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Amini B; Department of Musculoskeletal Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Kleinerman ES; Department of Pediatrics Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Gilchrist SC; Department of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.; Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Jazyk: angličtina
Zdroj: Journal of adolescent and young adult oncology [J Adolesc Young Adult Oncol] 2022 Jun; Vol. 11 (3), pp. 320-322. Date of Electronic Publication: 2021 Aug 12.
DOI: 10.1089/jayao.2021.0107
Abstrakt: Identification of anthracycline-induced muscle loss is critical for maintaining health in adolescent and young adult (AYA) cancer patients. We used routine chest computed tomography (CT) scans to investigate changes in skeletal muscle of 16 AYA sarcoma patients at thoracic vertebrae 4 (T4) after anthracycline treatment. CT images were examined at three time points (prechemotherapy, postchemotherapy, and 1 year). Significant changes in total skeletal muscle index and density were seen after chemotherapy ( p  = 0.021 and p  = 0.016, respectively) and at 1 year versus baseline (both p  < 0.05). This study supports the use of T4 as an early indicator of skeletal muscle loss in AYAs.
Databáze: MEDLINE